Air Pollution Increases Risk for Incident Atopic Dermatitis
The relationship between air pollutants and atopic dermatitis is evaluated.
Atopic Dermatitis
Cutaneous Adverse Reactions to COVID-19 Vaccine Rare, Transient
Clinicians report the cutaneous reactions experienced by healthcare workers who received the Pfizer COVID-19 vaccine.
Atopic Dermatitis Not Tied to a Higher Rate of SARS-CoV-2 Infection
The rates of SARS-CoV-2 infection, hospitalization, and mortality in patients with or without AD are compared.
Dupilumab Gets FDA Priority Review for Atopic Dermatitis in Children
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab as an add-on maintenance treatment for pediatric atopic dermatitis.
Dupilumab Associated With Favorable Benefit/Risk Ratio for Atopic Dermatitis
This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
Long-Term Dupilumab Therapy Shows Sustained Improvements in Atopic Dermatitis Symptoms
The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe atopic dermatitis.
Asthma, Atopic Dermatitis May Predispose to Behavioral and Emotional Problems
Although atopic dermatitis in infancy was not associated with later behavioral problems, at 6.5 years old, children who experienced asthma or atopic dermatitis symptoms within the past year were at increased risk for concomitant emotional problems.
Atopic Dermatitis Associated With Food Allergy Is Unique Endotype
Children with both atopic dermatitis and food allergy have stratum corneum abnormalities that distinguish them from other atopic dermatitis endotypes and children without atopic disease.
Children With Atopic Dermatitis Have Worse Sleep Quality
Children with atopic dermatitis were more likely to report worse sleep quality, with increased odds of experiencing more sleep-quality disturbances.
Dupilumab Approved to Treat Adolescents With Moderate-to-Severe Atopic Dermatitis
The FDA has approved Dupixant to treat moderate-to-severe atopic dermatitis in adolescent patients.
- Loading...
Loading...
Next post in Allergies
Loading... 
Loading...